Dan Liao

Dan Liao

Auto-generated profile, based on publicly available information

Dan Liao

Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
DLDan Liao
Dan Liao
LZLi Zhong
Li Zhong
JYJunqiang Yin
Junqiang Yin
CZCuiling Zeng
Cuiling Zeng
XWXin Wang
Xin Wang
TKTiebang Kang
Tiebang Kang

18 December 2022 in Advanced Science
Verified
Journal Article
Open access
CZCuiling Zeng
Cuiling Zeng
LZLi Zhong
Li Zhong
WLWenqiang Liu
Wenqiang Liu
YZYu Zhang
Yu Zhang
XYXinhao Yu
Xinhao Yu
DLDan Liao
Dan Liao
Rab22a‐NeoF fusion protein has recently been reported as a promising target for osteosarcoma lung metastasis. However, how this fusion protein is regulated in cells remains unknown. Here, using multiple screenings, it is reported that Rab22a‐NeoF1 fusion protein is degraded by an E3 ligase STUB1 via the autophagy receptor NDP52‐mediated lysosome pathway, which is facilitated by PINK1 kinase. Mechanistically, STUB1 catalyzes the K63‐linked ubiquitin chains on lysine112 of Rab22a‐NeoF1, which is responsible for the binding of Rab22a‐NeoF1 to NDP52, resulting in lysosomal degradation of Rab22a‐NeoF1. PINK1 is able to phosphorylate Rab22a‐NeoF1 at serine120, which promotes ubiquitination and degradation of Rab22a‐NeoF1. Consistently, by upregulating PINK1, Sorafenib and Regorafenib can inhibit osteosarcoma lung metastasis induced by Rab22a‐NeoF1. These findings reveal that the lysosomal degradation of Rab22a‐NeoF1 fusion protein is targetable for osteosarcoma lung metastasis, proposing that Sorafenib and Regorafenib may benefit cancer patients who are positive for the RAB22A‐NeoF1 fusion gene.

24 November 2023 in Science Advances
Verified
Journal Article
Open access
LZLi Zhong
Li Zhong
JWJingxuan Wang
Jingxuan Wang
WCWanqi Chen
Wanqi Chen
DLDongming Lv
Dongming Lv
RZRuhua Zhang
Ruhua Zhang
DLDan Liao
Dan Liao
Osteosarcoma is a highly aggressive cancer and lacks effective therapeutic targets. We found that L3MBTL2 acts as a tumor suppressor by transcriptionally repressing IFIT2 in osteosarcoma. L3MBTL2 recruits the components of Polycomb repressive complex 1.6 to form condensates via both Pho-binding pockets and polybasic regions within carboxyl-terminal intrinsically disordered regions; the L3MBTL2-induced condensates are required for its tumor suppression. Multi-monoubiquitination of L3MBTL2 by UBE2O results in its proteasomal degradation, and the UBE2O/L3MBTL2 axis was crucial for osteosarcoma growth. There is a reverse correlation between L3MBTL2 and UBE2O in osteosarcoma tissues, and higher UBE2O and lower L3MBTL2 are associated with poorer prognosis in osteosarcoma. Pharmacological blockage of UBE2O by arsenic trioxide can enhance L3MBTL2-induced condensates and consequently suppress osteosarcoma growth. Our findings unveil a crucial biological function of L3MBTL2-induced condensates in mediating tumor suppression, proposing the UBE2O-L3MBTL2 axis as a potential cancer therapeutic target in osteosarcoma.

1 January 2018 in Theranostics
Verified
Journal Article
Open access
XLXinchun Li
Xinchun Li
LZLi Zhong
Li Zhong
ZWZhuo Wang
Zhuo Wang
HCHuiming Chen
Huiming Chen
DLDan Liao
Dan Liao
TKTiebang Kang
Tiebang Kang
IRS4, a member of the insulin receptor substrate protein family, can induce constitutive PI3K/AKT hyperactivation and cell proliferation even in the absence of insulin or growth factors and promote tumorigenesis, but its regulation has only been explored at the transcriptional level.

7 February 2024 in Cancer Letters
Verified
Journal Article
Closed access
WGWeijie Gao
Weijie Gao
JZJing Zhou
Jing Zhou
JHJintao Huang
Jintao Huang
ZZZhiguang Zhang
Zhiguang Zhang
WCWanqi Chen
Wanqi Chen
LZLi Zhong
Li Zhong

8 January 2026 in Communications Biology
Verified
Journal Article
Open access
PDF file
QJQian Jiang
Qian Jiang
CPChen Peng
Chen Peng
WMWenhao Mao
Wenhao Mao
ZYZhuo Yu
Zhuo Yu
YFYadan Feng
Yadan Feng
TSTing Sun
Ting Sun
Cuproptosis, a copper-dependent cell death pathway, is emerging as a potential cancer treatment strategy. N6-methyladenosine (m6A), the predominant eukaryotic RNA modification, regulates various cell death mechanisms; however, its role in cuproptosis within hepatocellular carcinoma (HCC) remains unclear. Here, we found that METTL3 expression and m6A modification are upregulated during cuproptosis in HCC cells. Mechanistically, METTL3 mediated m6A modification of FDX1 mRNA, whereas the m6A reader FMR1 inhibited FDX1 translation. Consequently, METTL3 conferred resistance to cuproptosis by suppressing FDX1 protein expression in an m6A-FMR1-dependent manner. Knockdown or pharmacological inhibition of METTL3 sensitized HCC cells to elesclomol-Cu-induced cuproptosis and effectively suppressed HCC xenograft growth in vivo. Clinically, elevated METTL3 expression was associated with poor HCC prognosis, and the protein expression of METTL3 and FDX1 was negatively correlated in HCC tissues. In conclusion, our findings identify an METTL3-mediated m6A regulatory mechanism controlling cuproptosis sensitivity, revealing METTL3 inhibition as a promising therapeutic strategy for HCC.